Cash Flow Glaxosmi. Pharma Cash flow Statement
Figures in Cr
Consolidated Cash Flow Results
Mar'26
Mar'25
Mar'24
Mar'23
Mar'22
Mar'21
No of Months
12
12
12
12
12
12
Profit Before Tax
1,385.00
1,255.00
959.00
841.00
2,475.00
723.00
Adjustment
-65.00
-68.00
-45.00
-40.00
-1,636.00
-25.00
Changes In working Capital
-98.00
184.00
61.00
-45.00
119.00
45.00
Cash Flow after changes in Working Capital
1,221.00
1,371.00
975.00
755.00
959.00
743.00
Cash Flow from Operating Activities
903.00
1,289.00
582.00
484.00
810.00
577.00
Cash Flow from Investing Activities
396.00
-45.00
8.00
807.00
-405.00
418.00
Cash Flow from Financing Activities
-737.00
-769.00
-561.00
-1,543.00
-524.00
-695.00
Net Cash Inflow / Outflow
563.00
474.00
29.00
-251.00
-119.00
300.00
Opening Cash & Cash Equivalents
538.00
64.00
34.00
286.00
405.00
104.00
Cash & Cash Equivalent on Amalgamation / Take over / Merger
0.00
0.00
0.00
0.00
0.00
0.00
Cash & Cash Equivalent of Subsidiaries under liquidations
0.00
0.00
0.00
0.00
0.00
0.00
Translation adjustment on reserves / op cash balances foreign subsidiaries
0.00
0.00
0.00
0.00
0.00
0.00
Effect of Foreign Exchange Fluctuations
0.00
0.00
0.00
0.00
0.00
0.00
Closing Cash & Cash Equivalent
1,102.00
538.00
64.00
34.00
286.00
405.00
Figures in INR Cr
Seasonal companies are compared with the same quarter last year
Seasonal companies are compared with the same quarter last year
Compare Cash Flow Results of Glaxosmi. Pharma
Figures in Cr
consolidated Cash Flow Results
Change(INR)
Change(%)
Profit Before Tax
1385.39
1189.16
196.00
16.50%
Adjustment
-65.25
112.11
-177.00
-158.20%
Changes In working Capital
-98.17
178.93
-276.00
-154.87%
Cash Flow after changes in Working Capital
1221.97
1480.2
-259.00
-17.45%
Cash Flow from Operating Activities
903.3
1157.23
-254.00
-21.94%
Cash Flow from Investing Activities
396.98
-376.52
772.00
205.43%
Cash Flow from Financing Activities
-737.08
-733.41
-4.00
-0.50%
Net Cash Inflow / Outflow
563.2
47.3
516.00
1090.70%
Opening Cash & Cash Equivalents
538.85
129.49
409.00
316.13%
Cash & Cash Equivalent on Amalgamation / Take over / Merger
0
0
0.00
0.00%
Cash & Cash Equivalent of Subsidiaries under liquidations
0
0
0.00
0.00%
Translation adjustment on reserves / op cash balances foreign subsidiaries
0
0
0.00
0.00%
Effect of Foreign Exchange Fluctuations
0
0
0.00
0.00%
Closing Cash & Cash Equivalent
1102.05
176.79
926.00
523.37%
Cash Flow - Snapshot (Consolidated) - Mar'26
YoY Growth in year ended Mar 2026 is -29.97% vs 121.62% in Mar 2025
Mar'26
Mar'25
Change(%)
Cash Flow from Operating Activities
903.30
1,289.90
-29.97%
